NCG Mouse

p.small { line-height: 0.9; } p.big { line-height: 1.8; } NCG mice are triple immunodeficient and lack functional/mature T, B, and NK cells, and have reduced macrophage and dendritic cell function. These animal models have the ability to host xenograft cells, tissue, and human immune system components.This mouse model is ideal for oncology, immunology, tumor biology, infectious disease, graft-versus-host disease (GvHD), diabetes, regenerative medicine, hematopoiesis and tissue transplant studies. The NCG mouse model can also be utilized to create humanized mice by engrafting PBMCs or CD34 stem cells to closely mimic the human immune system.The NCG mouse is the foundation for further strains and variants including:Pre-humanized CD34+ and PBMC NCG miceThe NCG portfolio of NCG variant mouse models, capable of hosting human tissues and recapitulating the human immune systemOrigin and CRISPR/Cas9*-Generated MutationCo-developed by Nanjing Biomedical Research Institute of Nanjing University and Nanjing Galaxy Biopharma in 2014 and transferred to Charles River in 2016. The NCG mouse model was created by sequential CRISPR-Cas9 editing of the Prkdc and Il2rg loci in the NOD/Nju mouse, generating a mouse coisogenic to the NOD/Nju.The NOD/Nju carries a mutation in the Sirpa (SIRP α) gene that allows for engrafting of foreign hematopoietic stem cells. The Prkdc knockout generates a SCID-like phenotype lacking proper T-cell and B-cell formation. The knockout of the Il2rg gene further exacerbates the SCID-like phenotype while additionally resulting in a decrease of NK cell production.Strain HighlightsProven robust engraftment of human immune cells and tumorsClean CRISPR knockout of Prkdc and Il2rg reduces the risk of spontaneous thymic lymphomas, extending study windowsCompetitive pricing – scale your studies without stretching budgetsStrong availability – reliable supply for longer projectsNCG variants – optimized for CAR-T, NK cell, and immuno-oncology studies*CRISPR/CAS9 is used under licenses to granted and pending US and international patents from The Broad Institute and ERS Genomics Limited.